Creative Medical Technology Holdings Reports 3Q 2026 Financial Results

Creative Medical Technology Holdings reported no revenue in the third quarter of 2026, unchanged from a year earlier. Its net loss widened as research and development expenses rose 244% to $1.6 million, including $1.17 million in stock-based expenses tied to its BioDefense investment and higher development costs across other platforms; lower ADAPT trial expenses partly offset the increase. General and administrative expenses climbed 43% to $1.1 million, driven by higher compensation and legal fees.